Veru VERU shares are trading higher on Monday after the company presented preclinical data for its breast cancer treatment.
Veru is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility, and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Sexual health business and Research & development.
Veru shares were trading up 46.42% at $9.30 on Monday during the time of publication. The stock has a 52-week high of $10.83 and a 52-week low of $2.30.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
